author-photo

John M. Pagel

Fred Hutchinson Cancer Research Center
University of Washington

464

Papers

11492

Citations

Citation Trend

Filter By

Papers (334) Sort By

Journal Conference Others

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24)

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare).

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (7)